KoBioLabs
A Global Bio Company that Leads the Bio Industry
KoBioLabs
KoBioLabs
History
-
July 2021
KBLP-007 phase 2a study approval (US)
June 2021
KBLP-007 phase 2a study IND filing (US)
March 2021
KBLP-002 phase 1 study completion
-
November 2020
Licensing agreement with Kolmar Korea Holdings
KOSDAQ stock market enlisted (IPO)
August 2020
US FDA IND Approval of KBLP-001 phase 2 study
May 2020
KBLP-001 phase 1 study completion
April 2020
KBLP-007 Non-IND human PoC study for ulcerative colitis initiated (KR)
KBLP-002 Non-IND human PoC study for asthma initiated (KR)
March 2020
KBLP-002 Phase 1 HREC approval (AU)
-
September 2019
KBLP-001 phase 1 study HREC approval (AU)
₩27b Pre-IPO funding completed
February 2019
Attracted ₩4b strategic investment from CJ CheilJedang Co., Ltd.
-
December 2018
KBLF-001/KBLF-002 IRB approval of human study in Samsung Medical Center (KR)
(Non-IND human PoC study for atopic dermatitis)November 2018
KBLF-003 IRB approval of human study in Samsung Medical Center (KR)
(Non-IND human PoC study for depression)Established KoBioLabs Australia Pty Ltd.
May 2018
Received the Ministry of Science and ICT Award
Psychiatric program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)
-
July 2017
₩10b Series A funding closed
Atopic dermatitis program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)
Chronic kidney disease program, selected as government sponsored project by MSS(Ministry of SMEs and Startups)
-
July 2016
C. diffinfection program, selected as government sponsored project by MSIP(Ministry of Science, ICT and Future Planning)
March 2016
₩1.5b Pre-Series A funding closed
-
May 2015
Corp R&D institute established
-
November 2014
Certification of Venture Business
August 2014
Kobiolabs, Inc. founded, a spin-off from Microbiome Center at Seoul National University